^
    Back
    Association details:
    Biomarker:HER-2 expression
    Cancer:Colorectal Cancer
    Drug:trastuzumab botidotin (A166) (HER2-targeted antibody-drug conjugate, Tubulin inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene

    Excerpt:
    ...Evaluable or measurable HER2 positive (by ISH or NGS) disease or HER2 expressing disease....
    Trial ID:
    NCT03602079
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO 2020
    Title:

    A phase I study of safety and pharmacokinetics of A166, a novel selective inhibitor of human epidermal growth factor receptor-2 in Chinese patients with advanced solid tumors

    Published date:
    05/28/2020
    Excerpt:
    Patients with HER2-expressing or amplified advanced solid tumors refractory to standard therapies were recruited....As of October 1, 2019 among 19 patients (breast cancer, colorectal cancer and gastric cancer)treated,no one experienced dose-limiting toxicity….A166 showed an acceptable safety profile and promising anti-tumor activity in patients with HER2-expressing advanced solid tumors.
    DOI:
    10.1200/JCO.2020.38.15_suppl.e13007